Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

Citation
M. Bijl et al., Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus, ANN RHEUM D, 60(5), 2001, pp. 523-526
Citations number
15
Categorie Soggetti
Rheumatology,"da verificare
Journal title
ANNALS OF THE RHEUMATIC DISEASES
ISSN journal
00034967 → ACNP
Volume
60
Issue
5
Year of publication
2001
Pages
523 - 526
Database
ISI
SICI code
0003-4967(200105)60:5<523:EOCMOP>2.0.ZU;2-N
Abstract
Objective-In systemic lupus erythematosus (SLE) autoantibody production is T cell dependent. For a proper T and B cell interaction, signalling of cost imulatory molecules on these cells is necessary. The expression of costimul atory molecules on peripheral blood lymphocytes in patients with SLE in con junction with disease activity was measured to evaluate whether expression of costimulatory molecules in SLE is increased. Methods-Thirteen patients with SLE with active disease, 10 patients with in active disease, and 14 controls entered the study. In addition, samples fro m 10 of the 13 patients with active disease could be studied at a moment of inactive disease as well. Isolated peripheral blood lymphocytes were stain ed for the lymphocyte subset markers CD4, CD8, CD19, their respective activ ation markers CD25, HLA-DR, CD38, and the costimulatory molecules CD40L, CD 28, CD40, CD80, and CD86. Expression was measured by flow cytometry. Results-Peripheral blood lymphocytes of patients with SLE showed signs of i ncreased activation at the moment of active disease. Almost all CD4+ T cell s expressed CD28, both in patients and in controls. CD80 expression on CD19 + B cells was low in both groups and did not correlate with disease activit y. In contrast, the percentage of CD19+ B cells expressing CD86 was increas ed in patients with SLE even in patients with inactive disease (p=0.04) and correlated with the SLEDAI score (p=0.0005) ana levels of anti-dsDNA (p=0. 006). No changes in CD40 or CD40L expression were found in the patients wit h SLE. Conclusion-In patients with SLE the expression of CD86 on CD19+ B cells is increased and is associated with disease activity, B cell activation, and l evels of anti-dsDNA. The increased CD86 expression will render (autoreactiv e) B cells more susceptible for T cells. This can facilitate autoantibody p roduction and might be a target for immunosuppressive treatments.